Abstract
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein1. While 70% of CF chromosomes carry a deletion of the phenylalanine residue 508 (δF508) of CFTR, roughly 5% of all CF chromosomes carry a premature stop mutation2. We reported that the aminoglycoside antibiotics G-418 and gentamicin can suppress two premature stop mutations [a stop codon in place of glycine residue 542 (G542X) and arginine residue 553 (R553X)] when expressed from a CFTR cDNA in HeLa cells3. Suppression resulted in the synthesis of full-length CFTR protein and the appearance of a cAMP-activated anion conductance characteristic of CFTR function. However, it was unclear whether this approach could restore CFTR function in cells expressing mutant forms of CFTR from the nuclear genome. We now report that C-418 and gentamicin are also capable of restoring CFTR expression in a CF bronchial epithelial cell line carrying the CFTR W1282X premature stop mutation (a stop codon in place of tryptophan residue 1282). This conclusion is based on the reappearance of cAMP-activated chloride currents, the restoration of CFTR protein at the apical plasma membrane, and an increase in the abundance of CFTR mRNA levels from the W1282X allele.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kerem, B.-S. et al. Identification of the cystic fibrosis gene: Genetic analysis. Science 245, 1073–1080 (1989).
Population variation of common cystic fibrosis mutations. Hum. Mutat. 4, 167–177 (1994).
Howard, M., Frizzell, R.A. & Bedwell, D.M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Med. 2, 467–469 (1996).
Bonetti, B., Fu, L., Moon, J. & Bedwell, D.M. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J. Mol. Biol. 251, 334–345 (1995).
Yang, Y. et al. Molecular basis of defective anion transport in L cells. Hum. Mol. Genet. 2, 1253–1261 (1993).
Zeitlin, P.L. et al. A cystic fibrosis bronchial epithelial cell line: Immortalization by adeno-12 SV40 infection. Am. J. Respir. Cell Mol. Biol. 4, 313–319 (1991).
Schwiebert, E.M., Flotte, T., Cutting, G.R. & Guggino, W.B. Both CFTR and outwardly rectifying chloride channels contribute to cAMP-stimulated whole cell chloride currents. Am. J. Physiol. 266, C1464–1477 (1994).
Gabriel, S.E., Clarke, L.L., Boucher, R.C. & Stutts, M.J. CFTR and outwardly rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 363, 263–266 (1993).
Egan, M.E. et al. Defective regulation of outwardly rectifying chloride channels by protein kinase A corrected by insertion of CFTR. Nature 358, 581–584 (1992).
Schoumacher, R. et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc. Natl. Acad. Sci, USA 87, 4012–4016 (1990).
Bradbury, N. et al. Regulation of plasma membrane recycling by CFTR. Science 256, 530–532 (1992).
Prince, L.S., Workman, R.B. & Marchase, R.B. Rapid endocytosis of the cystic fibrosis transmembrane conductance regulator chloride channel. Proc. Natl. Acad. Sci. USA 91, 5192–5196 (1994).
Tousson, A., Fuller, C.M. & Benos, D.J. Apical recruitment of CFTR in T-84 cells is dependent on cAMP and microtubules but not calcium or microfilaments. J. Cell Sci. 109, 1325–1334 (1996).
Cheng, S.H. et al. Defective intracellular transport and processing is the molecular basis of most cystic fibrosis. Cell 63, 827–834 (1990).
Hamosh, A., Rosenstein, B.J. & Cutting, G. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum. Mol. Genet. 1, 542–544 (1992).
Fuller, C.M., Howard, M., Bedwell, D.M., Frizzell, R.A. & Benos, D.J. Antibodies against the cystic fibrosis transmembrane regulator. Am. J. Physiol. 262, C396–C404 (1992).
Demolombe, S. et al. Abnormal subcellular localization of mutated CFTR protein in a cystic fibrosis epithelial cell line. Eur. J. Cell Biol. 65, 214–219 (1994).
Hamosh, A. et al. Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J. Clin. Invest. 88, 1880–1885 (1991).
Shoshani, T. et al. Association of a nonsense mutation (Wl 282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am. J. Hum. Cenet. 50, 222–228 (1992).
Hasty, P. et al. A severe phenotype in mice with a termination mutation in exon 2 of the cystic fibrosis gene. Somat. Cell Mol. Genet. 21, 177–187 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bedwell, D., Kaenjak, A., Benos, D. et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 3, 1280–1284 (1997). https://doi.org/10.1038/nm1197-1280
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm1197-1280
This article is cited by
-
Ataluren suppresses a premature termination codon in an MPS I-H mouse
Journal of Molecular Medicine (2022)
-
Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy
Journal of Experimental & Clinical Cancer Research (2021)
-
Nonsense suppression therapies in human genetic diseases
Cellular and Molecular Life Sciences (2021)
-
Serum starvation enhances nonsense mutation readthrough
Journal of Molecular Medicine (2019)
-
Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons
Molecular Medicine (2018)